You are here

  • Home
  • Archive
  • Volume 2017, Issue
  • Effect of autologous adipose-derived mesenchymal stem cell therapy in the treatment of a post-traumatic chondral defect of the knee

Article Text

Article menu

Download PDFPDF

XML
Novel treatment (new drug/intervention; established drug/procedure in new situation)
CASE REPORT
Effect of autologous adipose-derived mesenchymal stem cell therapy in the treatment of a post-traumatic chondral defect of the knee
  1. Julien Freitag1,2,3,
  2. Douglas Li4,
  3. James Wickham2,
  4. Kiran Shah3,
  5. Abi Tenen3,5
  1. 1Melbourne Stem Cell Centre, Box Hill, Victoria, Australia
  2. 2School of Biomedical Sciences, Charles Sturt University-Orange Campus, Orange, New South Wales, Australia
  3. 3Magellan Stem Cells, Box Hill North, Victoria, Australia
  4. 4Orthopaedic Associates Melbourne, East Melbourne, Victoria, Australia
  5. 5Monash University, Clayton, Victoria, Australia
  1. Correspondence to Dr Julien Freitag, julien.freitag{at}mscc.com.au

Summary

Isolated chondral defects have a limited capacity to heal and predispose to the development of osteoarthritis. Current surgical management can be unpredictable in outcome. Improved understanding of the action of mesenchymal stem cells (MSCs) has seen renewed interest in their role in cartilage repair. A 26-year-old athlete presented with a post-traumatic, isolated patella chondral defect. The patient underwent an arthroscopy with removal of a chondral loose body. After failure to symptomatically improve 12 months following surgery, the patient received intra-articular autologous adipose-derived mesenchymal stem cell (ADMSC) therapy.

  • orthopaedics
  • knee injuries
  • sports and exercise medicine

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

https://doi.org/10.1136/bcr-2017-220852

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors JF, DL, JW, KS and AT were involved in the data acquisition, analysis of data and drafting of the report. JF, DL, JW, KS and AT have read and approved the final manuscript. JF, DL, JW, KS and AT agreed to be accountable for the article and to ensure that all questions regarding the integrity of the article are investigated and resolved.

    • Competing interests JF is affiliated with Magellan Stem Cells and is a member of Magellan Stem Cells Clinical and Scientific Advisory Board. KS is affiliated with Magellan Stem Cells and is the Chief Scientific Officer of Magellan Stem Cells. AT is affiliated with Magellan Stem Cells.

    • Patient consent Obtained.

    • Provenance and peer review Not commissioned; externally peer reviewed.